Phentermine Articles
Stock Commentary - New York week to March 23, 2009
30 March 2009
Vivus announces $65 million offering
11 August 2008
Stock Commentary - New York week to July 7, 2008
14 July 2008
Stock Commentary - New York week to May 26, 2008
2 June 2008
MIP and Superlco launch new SPE for amphetamines
14 January 2008
UPDATE: 2007 NASSO conference hears encouraging data on GSK's alli, Orexigen's Contrave et al
29 October 2007
Vivus' Qnexa boosts QoL in obese patients
29 October 2007
Caraco's generic version of Adipex-P OKed by FDA
3 September 2007
Stock Commentary - New York week to August 6, 2007
13 August 2007
Vivus' 2nd-qtr loss grows 16% on Qnexa costs
13 August 2007
Stock Commentary - New York week to July 23, 2007
30 July 2007
Vivus' 1st-qtr 2007 net loss narrows to $7.4M
21 May 2007
Stock Commentary - New York week to Nov 20, 2006
27 November 2006
Vivus raises $33.6 million
27 November 2006
Stock Commentary - New York week to Nov 6, 2006
13 November 2006
Stock Commentary - New York week to July 10, 2006
17 July 2006
Stock Commentary - New York week to May 15, 2006
22 May 2006
Vivus' Onexa performs well in obesity study
15 May 2006
3M explores options for pharma business
10 April 2006
Manhattan's obesity drug: strong results
6 June 2005
FDA OKs Lannett's phentermine ANDA
22 April 2005
Novartis to invest in Polish generics
24 May 2004
Euro Court rejects Commission drug ban
4 August 2003
European court overturns obesity drug ban
3 February 2003
Faulding sales rise 17.5%, boosted by pharma
9 August 2001
Ruling permits obesity drug class action
24 November 2000
MCA reinstates phentermine license
23 August 2000
Antiobesity drugs to be banned in EU
6 April 2000
Antiobesity drugs to be banned in EU
31 March 2000
Merger with Roberts going smoothly at Shire as revenues rise 30%
29 February 2000
Xenical, Meridia drive US antiobesity drugmarket
15 November 1999
CPMP seeks ban on phentermine, etc
29 September 1999
AHP will appeal Texas Pondamin ruling
9 August 1999
US doctor charged over Internet Rxing offenses
13 July 1999
Medeva confident about its future
12 February 1999
New UK obesity guidelines highlight role of drugs
25 January 1999
Medeva Files For European Approval Of Hepagene
27 October 1998
Phentermine To Blame for Fen-Phen Side Effects?
1 September 1998
Wyeth Withdraws Duract Due To Serious Liver Events
24 June 1998
Redux Study Casts Doubt On Valve Disease Problem
1 April 1998
UK's Medeva Redefining Product Portfolio
18 February 1998
Knoll Starts Distribution Of Meridia For Obesity
13 February 1998
Knoll's High Hopes For Its Obesity Drug Sibutramine
15 January 1998
Medeva Bladder Cancer Drug Filed In USA
15 January 1998
Stock Commentary Europe
6 January 1998
US Approval For Knoll's Obesity Drug Meridia
27 November 1997
American Home Doesn't Fear Diet Pill Law Suits
6 October 1997
Call For Increased Drug Safety Monitoring
24 September 1997
Servier Defends Dietary Drugs
24 September 1997
Senate Vote On FDA Reform/PDUFA
17 September 1997
Wyeth-Ayerst Recalls Redux And Pondimin
17 September 1997
Wyeth To Begin Redux Neurotoxicity Study
4 September 1997
US Drug & Biotech Firms Post Quarterly Results
14 August 1997
European And London Stock Comment
24 July 1997
Medeva's Growth Dulled By "Fen-Phen" Effect
17 July 1997
Heart Disease Link To Diet Drugs Prompts FDA Action
15 July 1997
Short-Term Difficulties For Medeva?
8 April 1997
Obesity Drug Sales Show Strong Rise In January
24 March 1997
Strong Growth In 1996 As Medeva Builds In the USA
24 February 1997
Medeva Takes On Single Isomer Methylphenidate
27 January 1997
UK Government Block Ban On Slimming Drugs
5 August 1996
Concerns Around Medeva Acquisition
24 June 1996
UK DoH Starts Talks On Slimming Drugs
15 May 1995
COMBINATION THERAPY FOR OBESITY
8 November 1993
Showing 1-71 of 71 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
